Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
3(17%)
Results Posted
27%(3 trials)

Phase Distribution

Ph not_applicable
12
67%
Ph early_phase_1
1
6%
Ph phase_2
3
17%
Ph phase_4
2
11%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution18 total trials
Early Phase 1First-in-human
1(5.6%)
Phase 2Efficacy & side effects
3(16.7%)
Phase 4Post-market surveillance
2(11.1%)
N/ANon-phased studies
12(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

18

all time

Status Distribution
Active(3)
Completed(11)
Terminated(1)
Other(3)

Detailed Status

Completed11
Recruiting3
unknown2
Suspended1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.6%)
Phase 23 (16.7%)
Phase 42 (11.1%)
N/A12 (66.7%)

Trials by Status

recruiting317%
completed1161%
suspended16%
unknown211%
withdrawn16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT06806267Not Applicable

Study of the Effectiveness of VRET Combined With tDCS in the Treatment of PTSD in Ukrainian Veterans and Civilians

Recruiting
NCT04887116Early Phase 1

Piloting Virtual Reality Environments to Treat PTSD in Healthcare Workers

Recruiting
NCT07192367Phase 4

Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder

Recruiting
NCT05841329Not Applicable

Efficacy of tDCS to Enhance Virtual Reality Exposure Therapy Response in Acrophobia

Completed
NCT04504773Not Applicable

Using Immersive Virtual Reality to Treat Pediatric Anxiety

Completed
NCT03917433Not Applicable

Augmenting Virtual Reality Exposure Therapy for Acrophobia

Suspended
NCT00734422Phase 2

Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants

Completed
NCT01965366Phase 4

Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD

Completed
NCT02933684Phase 2

D-Cycloserine and Virtual Reality Exposure Therapy

Withdrawn
NCT03000478Not Applicable

Virtual Reality Exposure Therapy for Combat

Unknown
NCT01442805Not Applicable

Use of Virtual Reality in the Treatment of Flying Phobia

Completed
NCT01746667Not Applicable

Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia

Completed
NCT01623830Not Applicable

Targeting Reconsolidation to Prevent Return of Fear

Completed
NCT02990208Not Applicable

Diaphragmatic Breathing During Virtual Reality Exposure Therapy for Aviophobia

Completed
NCT02973919Not Applicable

EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome

Completed
NCT00356278Phase 2

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

Completed
NCT02379949Not Applicable

Virtual Reality Exposure Therapy for the Treatment of Social Phobia

Completed
NCT01037101Not Applicable

D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights

Unknown

All 18 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
18